BillionToOne (BLLN) Q2 2026 earnings review
Growth Engine Runs Hot, but Sequential Margins Cool Down
BillionToOne continues to deliver impressive top-line growth, with Q2 revenue up 64% YoY to $109.4M. The company proved its oncology segment is a genuine second engine, surging 176% YoY. However, sequentially, the narrative is more complicated. Following a Q1 boosted by $9.2M in true-up revenues, Q2 revenue was essentially flat sequentially, and the core Prenatal segment actually contracted from Q1 levels. Meanwhile, the negative gross margin mix shift from the faster-growing oncology business caused operating margins to compress back to 5% from Q1's 16%. Management reiterated FY26 guidance, implying a back-half acceleration in absolute dollars, but the margin trajectory needs close monitoring.
🐂 Bull Case
Oncology revenue hit $13.7M, an accelerating 176% YoY growth rate. The continued sequential step-ups prove NorthStar is gaining real clinical traction, validating the company's multi-product platform thesis.
Overall ASP rose 21% YoY to $551. Even without Q1's massive true-up tailwinds, the structural improvements from Anthem and UnitedHealthcare in-network contracts are successfully holding ASPs at elevated levels.
🐻 Bear Case
Prenatal testing revenue dropped sequentially from $97.7M in Q1 to $94.2M in Q2. Even accounting for Q1's true-ups, this suggests the core cash-cow segment is experiencing a significant growth deceleration.
Management's prior warning about oncology's lower margins dragging on overall profitability materialized this quarter. Operating income plummeted from $17.8M in Q1 to $5.5M in Q2 as cost-per-test increased.
⚖️ Verdict: ⚪
Neutral. The YoY comparisons remain spectacular, and staying GAAP profitable while growing 64% is rare. However, the sequential flattening of top-line revenue and the sharp contraction in operating margin indicate that the 'Rule of 100 plus' hyper-growth phase is beginning to normalize.
Key Themes
Oncology Segment Hyper-Growth
The Oncology business is accelerating, growing 176% YoY to $13.7M. This segment has grown sequentially every quarter over the last year, expanding from $4.9M in 25Q2. It now represents 12.5% of total revenue (up from 7.3% a year ago). The continued adoption of NorthStar Select and NorthStar Response proves the company can successfully diversify beyond its prenatal roots.
Reversing Operating Leverage and Mix Shift
In Q1, the company boasted a 16% GAAP operating margin. In Q2, this compressed significantly to just 5% ($5.5M operating income vs $17.8M in Q1). Management explicitly noted that overall cost-per-test increased slightly YoY because the faster-growing oncology products have higher production costs. This structural margin drag will likely cap profitability as long as oncology outpaces prenatal growth, especially before NorthStar Response secures Medicare coverage.
Prenatal Segment Sequential Contraction
Despite 55% YoY growth, Prenatal testing revenue reversed sequentially, falling to $94.2M from Q1's $97.7M. While Q1 was heavily inflated by $9.2M in true-up revenues, the lack of sequential absolute dollar growth in the company's foundational segment is a red flag that warrants close monitoring, as it funds the entirety of the R&D and oncology commercialization efforts.
Relentless Pipeline and TAM Expansion
The company continues to aggressively expand its total addressable market through product iteration. It announced a 130-gene panel expansion for the Unity Fetal Risk Screen (launching August 17), creating the largest single-gene NIPT panel available. Additionally, Northstar Origin (an add-on tissue-of-origin feature for uncertain cancer diagnoses) launches September 1. This rapid cadence of product enhancements keeps competitors on the defensive.
Stable ASP Environment Holds
Overall Average Selling Price (ASP) was $551, up 21% YoY. While this is down slightly from Q1's artificially inflated $571 (due to true-ups), it proves that the foundational in-network contract wins with Anthem and UnitedHealthcare are driving sustainable, structural improvements in reimbursement and cash collection.
Other KPIs
FCF remained positive, dropping slightly from Q1's $11.0 million but showing a complete reversal from the $1.7M cash burn in the same quarter last year. The company ended the quarter with a massive $548.6M cash hoard, providing exceptional runway for the upcoming MRD launch.
Accelerating absolute volume. Up 35% YoY from 145,000 in 25Q2, and up sequentially from 188,000 in Q1. This indicates that while revenue flattened sequentially due to true-up dynamics, clinical demand and physical test utilization continue to scale aggressively.
Guidance
Stable. The company reiterated its full-year guidance, representing 48% to 52% YoY growth. With H1 actuals at $217.8M, the midpoint implies H2 revenue of roughly $239.7M. This requires sequential dollar growth to resume in H2, though the YoY percentage growth will naturally decelerate due to the law of large numbers.
Management expects to continue generating profitability 'similar to current levels' even with significant continued investments. Given the drop from a 16% to 5% operating margin this quarter, investors will want clarity on whether 'current levels' refers to Q2's 5% baseline or the blended H1 average.
Key Questions
Prenatal True-Up Granularity
Prenatal revenue declined sequentially by $3.5M. Exactly how much of Q1's $9.2M total true-up belonged to the Prenatal segment, and what was the true underlying sequential volume and revenue growth for Prenatal in Q2?
Oncology Margin Timeline
With overall cost-per-test creeping up due to the oncology mix shift, at what scale or specific reimbursement milestone (e.g., MolDX for Response) does the Oncology segment achieve gross margin parity with the Prenatal segment?
Unity Confirm Early Read
Unity Confirm launched on May 1st. While direct revenue was expected to be minimal, are you seeing the intended strategic effect—is the exclusivity of Confirm actively pulling through new frontline Unity aneuploidy screening volumes?